Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 5, 2025Journal of Clinical MedicineOpen Access

Antiplatelet Monotherapies for Long-Term Secondary Prevention Following Percutaneous Coronary Intervention

View Full Paper
Ask AI
Bookmark
Share

Authors

CLClaudio LaudaniDGDaniele GiacoppoAGAntonio Greco

Discussion

Loading...

Member takes

Overview

Review highlights the efficacy of P2Y12 inhibitor monotherapy for secondary prevention in CAD post-PCI, suggesting it may reduce bleeding risks effectively.

Key Points

  • Main finding reveals P2Y12 inhibitor monotherapy may effectively reduce bleeding in CAD patients post-PCI compared to standard dual antiplatelet therapy.
  • Key evidence shows that while antiplatelet therapy is essential, aspirin monotherapy remains standard for many patients after PCI.
  • Approach involved reviewing current pharmacology and data on antiplatelet monotherapy in patients with coronary artery disease.
  • Significance lies in exploring alternatives to dual antiplatelet therapy, potentially improving safety without compromising efficacy in ischemic event prevention.

Cite This Study

Laudani et al. (2025) studied this question.

synapsesocial.com/papers/689522129f4f1c896c429929https://doi.org/10.3390/jcm14155536
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Antiplatelet Therapy in Chronic Coronary Artery Disease Patients With a History of Angioplasty. When is Aspirin Not Enough? A Systematic Review2025
  2. 2Aspirin or P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention for Acute Coronary Syndromes2025 · 23 citations
  3. 3Clopidogrel Vs Aspirin Monotherapy for Secondary Prevention After Percutaneous Coronary Intervention2026 · 1 citations
  4. 4Sequential administration of abbreviated (up to one month) dual antiplatelet therapy and Ticagrelor monotherapy versus standard dual antiplatelet therapy after percutaneous coronary intervention: A meta-analysis2025
  5. 5Efficacy of Ticagrelor Monotherapy in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: a Systematic Review2025